Multaq package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Multaq (Dronedarone Hydrochloride)

Multaq

Dronedarone Hydrochloride

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:

Multaq

Dronedarone Hydrochloride

Sourced from United Kingdom Source: United Kingdom
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Multaq (dronedarone) is an antiarrhythmic listed in our Heart and blood pressure medications directory and prescribed for atrial fibrillation (1.1) (2.1). Administered via the oral route, Multaq is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Multaq is a medication containing the active pharmaceutical ingredient dronedarone, classified pharmacologically as an antiarrhythmic (2.1). It is clinically indicated for the management of atrial fibrillation as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Heart and blood pressure medications section of our catalogue, patients and prescribers frequently review Multaq alongside related therapies such as Acebutolol, Aceon (Perindopril Erbumine), Acetylsalicylic Acid, and Adcirca (Tadalafil).

Official Indications and Usage

® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). (1.1)

Mechanism of Action and Pharmacology

The mechanism of action of dronedarone is unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown. (1.1) (1.1)

What is Atrial fibrillation?

Atrial fibrillation is an irregular heart rhythm that can increase the risk of stroke. Care may address heart rate, rhythm, and clot prevention. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Atrial fibrillation condition guide for appointment questions and related therapies (3.1).

Ordering Multaq from Canada for U.S. Delivery

U.S. patients can order Multaq (Dronedarone) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Multaq
Chemical / Generic Name Dronedarone
Pharmacological Class Antiarrhythmic
Therapeutic Category Heart and blood pressure medications
Molecular Formula C31H44N2O5S (2.1)
Molecular Weight 556.8 g/mol (2.1)
IUPAC Chemical Name N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
Bioavailability ~4% (1.1)
Protein Binding ~98% (1.1)
Elimination Half-Life ~13 to 19 hours (1.1)
Time to Peak Plasma Level (Tmax) 3 to 6 hours (2.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus
Routes of Administration Oral
Dosage Forms & Strengths 400 mg tablets are provided as white film-coated tablets for oral administration, oblong-shaped, engraved with a double wave marking on one side and
Primary Indications Atrial Fibrillation
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
PubChem CID 208898
FDA UNII Identifier JQZ1L091Y2
NLM RxNorm Concept ID (RxCUI) 854856, 854859
FDA Application License NDA022425
Official DailyMed SetID 3bd4006a-8bad-4909-ac6d-b6d84390155c
Catalogue Index Links Letter M Index · All Medications · All Categories

Directions

Dosage and Administration Overview

The recommended dosage of Multaq is 400 mg twice daily in adults. Multaq should be taken as one tablet with the morning meal and one tablet with the evening meal. Treatment with Class I or III antiarrhythmics (e.g., amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) or drugs that are strong inhibitors of CYP3A (e.g., ketoconazole) must be stopped before starting Multaq. Verify that females of reproductive potential are not pregnant prior to initiating Multaq. One tablet of 400 mg twice a day with morning and evening meals. (1.1)

Presentations and Strengths

400 mg tablets are provided as white film-coated tablets for oral administration, oblong-shaped, engraved with a double wave marking on one side and "4142" code on the other side. (1.1)

Administration Guidance

Take Multaq orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.

Missed Dose Guidance

If you miss a scheduled dose of Multaq, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Multaq is dronedarone (molecular formula C31H44N2O5S, molecular weight 556.8 g/mol) (2.1) (2.1).

Inactive Ingredients (Excipients)

According to the U.S. FDA product labeling, formulation excipients include core of the tablets: Colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, poloxamer 407, starch (1.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.

Cautions and important safety information

Boxed Warning

Warning: increased risk of death, stroke and heart failure in patients with decompensated heart failure or permanent atrial fibrillation In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure, Multaq doubles the risk of death. Multaq is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. (1.1)

Contraindications

Multaq is contraindicated in patients with (1.1):

  • Permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored).
  • Symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV symptoms.
  • Second or third-degree atrioventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker).
  • Bradycardia <50 bpm.
  • Concomitant use of strong CYP3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir.
  • Concomitant use of erythromycin.

Key Clinical Precautions

Before starting or continuing Multaq, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
  • Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
  • Hepatic (liver) effects: Elevations in liver enzymes or rare cases of severe hepatic injury have been reported. Baseline and periodic liver function tests may be recommended; seek medical evaluation for jaundice, dark urine, or persistent right-upper-abdominal pain.
  • Renal function and acute kidney injury: Changes in serum creatinine or estimated glomerular filtration rate (eGFR) can occur, particularly in patients with volume depletion, chronic kidney disease, or concomitant use of NSAIDs, ACE inhibitors, ARBs, or diuretics. Renal function should be assessed prior to initiation and periodically thereafter.

Pregnancy, Lactation, and Special Populations

Multaq may cause fetal harm when administered to a pregnant woman. In animal studies, dronedarone administered to pregnant rats and rabbits during the period of organogenesis caused multiple visceral (rats) and skeletal malformations (rats and rabbits) when administered at doses equivalent to or lower than the maximum recommended human dose (MRHD). There are no available data on dronedarone use in pregnant women to evaluate for a drug-associated risk of major birth defects or miscarriage or other adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. (1.1)

Interactions

Official Drug Interaction Overview

Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions (1.1):

  • Class I or III antiarrhythmics: Contraindicated.
  • Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels.
  • Calcium channel blockers (ccb): Initiate ccb with low dose and increase after ECG verification of tolerability.
  • Beta-blockers: May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability.
  • CYP3A inducers: Avoid concomitant use.
  • Grapefruit juice: Avoid concomitant use.
  • CYP3A substrates with a narrow therapeutic index (e.g., sirolimus and tacrolimus): Monitor and adjust dosage of concomitant drug as needed when used with Multaq.

Important Interaction Categories

Concomitant use of Multaq with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Warfarin and vitamin K antagonists (such as Coumadin (Warfarin Sodium) or Warfarin Generic in our Cardiovascular directory): Concomitant administration may alter prothrombin time and International Normalized Ratio (INR) or have additive effects on hemostasis and bleeding risk. More frequent INR monitoring and clinical observation for bleeding are recommended.
  • Digoxin (such as Lanoxin (Digoxin) or Digoxin Generic): Co-administration can affect P-glycoprotein transport or renal clearance of digoxin, altering serum digoxin concentrations. Appropriate clinical and laboratory monitoring of digoxin levels is advised.
  • Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.
  • Anticoagulants (such as Eliquis (Apixaban), Xarelto (Rivaroxaban), or Pradaxa (Dabigatran) in our Blood health directory): Combining multiple anticoagulants or agents that affect coagulation markedly increases the risk of major bleeding.

Side effects

Like all medications, Multaq can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
  • Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.
  • Pruritus (mild itching): Report any spreading rash, hives, or mucosal irritation to your healthcare provider.

Clinical Trial and Postmarketing Adverse Reactions

The following safety concerns are described elsewhere in the label (1.1):

  • New or worsening heart failure.
  • Liver Injury.
  • Pulmonary toxicity.
  • Hypokalemia and hypomagnesemia with potassium-depleting diuretics.
  • QT prolongation Most common adverse reactions (≥2%) are diarrhea, nausea, abdominal pain, vomiting, dyspepsia, bradycardia, skin issues (rashes, pruritus, eczema, dermatitis, dermatitis allergic), and asthenia The safety evaluation of dronedarone 400 mg twice daily in patients with AF or afl is based on 5 placebo-controlled studies, athena, euridis, adonis, erato and dafne. In these studies, a total of 6285 patients were randomized and treated, 3282 patients with Multaq 400 mg twice daily, and 2875 with placebo.

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Store at room temperature between 68°F to 77°F (20°C to 25°C): excursions permitted to 59°F-86°F (15°C-30°C),. (1.1)

Store Multaq in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

Frequently Asked Questions About Multaq

What is Multaq and what active ingredient does it contain?

Multaq is an antiarrhythmic containing the active pharmaceutical ingredient dronedarone (chemical formula C31H44N2O5S). It is supplied for oral administration and requires a valid prescription where applicable.

How does Multaq work in the body?

The mechanism of action of dronedarone is unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.

What conditions is Multaq prescribed to treat?

Multaq is primarily indicated for atrial fibrillation. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Multaq?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Multaq is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Multaq?

Commonly reported side effects of Multaq include feeling sick, vomiting, loose stools, abdominal pain, and itching. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Multaq?

Important interaction categories for Multaq include warfarin, digoxin, medicines that strongly affect CYP3A enzymes, and anticoagulants. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Multaq be used during pregnancy or breastfeeding?

Official prescribing information highlights pregnancy-related precautions for Multaq. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.

Do I need a prescription to buy Multaq online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Multaq (Dronedarone) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Multaq have a generic equivalent (Dronedarone) at a Canada pharmacy?

Currently, Multaq (Dronedarone) is dispensed in our catalogue as a brand-name formulation. Check our Dronedarone active ingredient hub for updates as licensed generic presentations become available.

How is Multaq shipped to U.S. residents, and how much does shipping cost?

Multaq ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Multaq prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Multaq prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Multaq (Dronedarone Hydrochloride) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Multaq. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) PubChem Compound Summary for cid 208898 (Dronedarone). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
  3. (3.1) MedlinePlus Medical Encyclopedia: Atrial Fibrillation. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  4. (4.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help